Feline diabetes care expands beyond insulin, with new cautions

Treatment options for feline diabetes are expanding, and that’s changing the clinical conversation. The VetGirl podcast with Dr. Chris Byers and dvm360’s coverage both reflect a profession moving from an insulin-only mindset toward a more nuanced model that includes oral SGLT2 inhibitors, nutrition strategy, and tighter patient selection. In the U.S., that shift has been driven by FDA approval of Bexacat in December 2022 and Senvelgo on August 10, 2023, giving veterinarians two oral options for certain newly diagnosed cats. (fda.gov)

The backdrop is familiar to anyone in practice: feline diabetes can be manageable, but twice-daily insulin, home monitoring, and recheck intensity can be a major hurdle for some pet parents. Oral therapy has opened the door for cases where injection adherence might otherwise be poor, but the regulatory language has been consistent that these drugs are not broad substitutes for insulin. Both FDA and manufacturer materials limit use to otherwise healthy cats with diabetes mellitus that have not previously been treated with insulin, and both highlight the risk of diabetic ketoacidosis or euglycemic DKA. (fda.gov)

The evidence base behind that shift is growing. FDA summaries report Bexacat was more than 80% effective in improving glycemic control in field studies, while the FOI summary for Senvelgo says its approval was supported by a field study enrolling 252 client-owned diabetic cats and concluded the product was safe and effective when used according to label precautions. Peer-reviewed publications have since added detail: a 2024 Journal of Veterinary Internal Medicine paper reported that velagliflozin as a once-daily oral stand-alone therapy was effective in the SENSATION study, and another JVIM study compared velagliflozin with twice-daily insulin injection in diabetic cats. (fda.gov)

At the same time, the safety and communication story is still evolving. In a March 1, 2024 warning letter, the FDA said Boehringer Ingelheim’s promotional communications for Senvelgo made false or misleading claims about safety and effectiveness, specifically because they contradicted the product’s boxed warning, contraindications, and approved indication. That matters because enthusiasm around easier administration can obscure the clinical reality: these are not low-touch drugs during initiation, and eDKA can present even when blood glucose is not dramatically elevated. FDA’s Dear Veterinarian letter on Senvelgo reinforces that ketonuria should prompt discontinuation and prompt insulin treatment, even if blood glucose is normal. (fda.gov)

Clinical educators are also pushing the profession to keep nutrition in the frame. dvm360’s “Beyond insulin” discussion emphasized individualized dietary planning around palatability, protein content, digestibility, and comorbidities, while more recent dvm360 commentary with internist Audrey Cook underscored familiar risk factors including obesity, sedentary indoor lifestyle, steroid exposure, and concurrent disease. That’s an important reminder that newer drugs haven’t replaced the basics of diabetic case workups or long-term metabolic management. (dvm360.com)

Expert reaction has been cautiously optimistic. dvm360 described Bexacat as a promising novel treatment while also laying out intensive early monitoring recommendations, including rechecks within 3 to 5 days and additional testing at weeks 2, 4, and 8, then every 90 days. AAHA coverage similarly stressed careful case selection for oral therapy candidates. Outside the approval studies, early real-world reports and reviews suggest clinicians are already exploring where SGLT2 inhibitors fit in less-than-ideal cases, but those experiences also reinforce why label restrictions and ketone vigilance remain central. (dvm360.com)

Why it matters: For veterinary professionals, the real update isn’t just that there are oral drugs now. It’s that feline diabetes management is becoming more stratified. Clinics may be able to help some pet parents start treatment faster, reduce injection-related resistance, and potentially improve adherence, but only if teams build solid protocols for screening, client education, ketone monitoring, and fast recognition of appetite loss, lethargy, dehydration, or weight loss. The practical upside is real, especially for newly diagnosed, otherwise healthy cats. The practical risk is also real if convenience messaging outruns case selection. (fda.gov)

What to watch: The next phase will likely center on real-world outcomes, refinement of candidate selection, and whether additional guidance from educators, specialty groups, or regulators further sharpens how oral SGLT2 inhibitors are positioned relative to insulin-first management in cats with more complicated disease. (pmc.ncbi.nlm.nih.gov)